Condition: Vascular Parkinsonism · Drug-induced Parkinsonism · Corticobasal Degeneration (CBD) · Sponsor: Beijing Tiantan Hospital
A quantitative evaluation method was developed for Parkinson's disease and other atypical parkinonism by integrating an innovative motor paradigm with perception technologies and artificial intelligence. Combined with traditional motor paradigms and the acute levodopa challenge test, this study aims to identify diagnostic cut-off values for PD and other atypical parkinonism, explore digital biomarkers for early and differential diagnosis, and establish a corresponding diagnostic model.
This description comes directly from the study's public registry record.
Tao Feng, MD · 86-13911125339 · bxbkyjs@sina.com
Lingyan Ma, MD · 86-13520873987 · Jennifer_MLY@163.com
Always discuss trial participation with your own doctor first.
| Beijing Tiantan Hospital, Affiliated to Capital Medical University | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06949865